Erythromycin Ethyl Succinate   



   
Description  

Erythromycin Ethyl Succinate

Chemical charasteristics : 
Erythromycin 2' - (ethyl butanedioate)
Formula and Molecular Weight:
C 4 3 H 7 5 N O 1 6 M W : 862 

Mode of Action : 

Erythromycin is a macrolide systemic antibiotic. This antibiotic penetrates bacterial cell membrane and reversibly binds to then 50S subunit of bacterial ribosomes. Translocation of peptides from then "A" or acceptor site to then "p" or donor site is prevented by antibiotic on EF-G and protein synthesis subsequently is inhibited.
Erythromycin is effective on actively dividing organisms.


Pharmacokinetics : 

Erythromycin is largely bound to plasma protein and freely dissociated bound fraction. After administration of Erythromycin, 90% of total Erythromycin absorted. After absorption, Erythromycin diffuses readily into most of the body fluids in Meningitis, and the passage of the drug across the blood-brain barrier is increased. In normal hepatic function cases, Erythromycin is concentrated dose can be recovered in the active form in the urine.


Half - life : 
Normal renal function : 1.4 to 2 hours .
Impaired renal function : 4.8 to 6 hours .

Indications : 

Erythromycin is used in treatment of respiratory tract infections (upper and lower), skin and/or soft tissue infections, pertusis (whooping cough), Diphtheria, Erythrasma, Intestinal Amebiasis (caused by Entamoeba histolytica), Conjunctivitis of the newborn, Pneumonia of infancy and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, Erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis and nongonococcal urethritis caused by Ureaplasma urealyticum. Other usages of the antibiotic are including:primary syphilis, legionnaire's disease, preventation of initial and recurrent attacks of rheumatic fever, acute pelvic inflammatory disease, infections due to Listeria monocytogenes and prevention of bacterial endocarditis. 


Bulk Production of Erythromycin Ethylsuccinate in Shafa plant : 
Erythromycin Ethylsuccinate is produced in Shafa-e-Sari plant by chemical synthesis method. In this plant there are all kind of equipments which is essential for high pure active pharmaceutical ingredients manufacturing (contain glass-lined, stainless steel reactors, continuous dryer, solvent recovery system, crystallizator and etc.) 
The product is in conformity with the latest international standards such as : USP/ BP/EP and IP. 


General Infomation : 
Erythromycin Ethylsuccinate is presented to pharmaceutical companies as an API in order to produce various forms of medicines (tablet, syrup, capsule) . 


The advantages of Shafa's Erythromycin Ethylsuccinate in comparison with the competitors are : 
- Unique purity quality
- Halal Certification awarded from Islamic Chamber Research & Information Center (ICRIC) 
- Production under GMP certificate (Good Manufacturing Practice) from Ministry of Health
- Production under ISO 9001 certificate 


Opportunities for Cooperation : 
Shafa Co. welcomes cooperation with other companies in the field of joint production and marketing. 


 

طراحی و سئو سایت توسط نونگار